专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2010254714A Methylene urea derivative 审中-公开
标题翻译：甲基脲衍生物
公开(公告)号：JP2010254714A
公开(公告)日：2010-11-11
申请号：JP2010179074
申请日：2010-08-09
申请人： Merck Patent Gmbh , メルクパテントゲゼルシャフトミットベシュレンクテルハフツングMerck Patent Gesellschaft mit beschraenkter Haftung
发明人： BUCHSTALLER HANS-PETER , WIESNER MATTHIAS , SCHADT OLIVER , AMENDT CHRISTIANE , ZENKE FRANK , SIRRENBERG CHRISTIAN , GRELL MATTHIAS , FINSINGER DIRK
IPC分类号： C07D213/81 , A61K31/44 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/5377 , A61P13/08 , A61P15/08 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P43/00 , C07D213/68 , C07D213/79 , C07D401/12 , C07D409/12 , C07D417/12
CPC分类号： C07D213/68 , A61K31/44 , A61K31/4439 , A61K45/00 , C07D213/75 , C07D213/79 , C07D213/81 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： PROBLEM TO BE SOLVED: To provide methylene urea derivatives, the methylene urea derivatives as pharmaceuticals, the methylene urea derivatives as inhibitors of raf-kinase, use of the methylene urea derivatives for the manufacture of pharmaceuticals, and a method for producing pharmaceutical compositions comprising the methylene urea derivatives, pharmaceutical compositions obtained by the methods and methods of treatment comprising administering the pharmaceutical compositions.
SOLUTION: The present invention relates to methylene urea derivatives of formula (I): A-D-B, the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of the pharmaceutical compositions and a method of treatment comprising administering the pharmaceutical compositions to a patient.
COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：待解决的问题：为了提供亚甲基脲衍生物，作为药物的亚甲基脲衍生物，作为raf激酶抑制剂的亚甲基脲衍生物，用于制备药物的亚甲基脲衍生物的用途，以及制备药物的方法包含亚甲基脲衍生物的组合物，通过治疗方法和方法获得的药物组合物，包括给予药物组合物。解决方案：本发明涉及式（I）的亚甲基脲衍生物：ADB，式（I）化合物作为raf-激酶抑制剂的用途，式（I）化合物用于药物组合物的制备和治疗方法，包括向患者施用药物组合物。版权所有（C）2011，JPO＆INPIT

2. 发明申请

WO0241910A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE EYE 审中-公开
标题翻译：用于治疗眼睛疾病的方法和组合物
公开(公告)号：WO0241910A2
公开(公告)日：2002-05-30
申请号：PCT/EP0112526
申请日：2001-10-30
申请人： MERCK PATENT GMBH , BENDER HANS MARKUS , HAUNSCHILD JUTTA , WIESNER MATTHIAS , LANG ULRICH , FRIEDLANDER MARTIN
发明人： BENDER HANS-MARKUS , HAUNSCHILD JUTTA , WIESNER MATTHIAS , LANG ULRICH , FRIEDLANDER MARTIN
IPC分类号： C07D311/22 , A61K9/00 , A61K9/10 , A61K9/51 , A61K31/352 , A61K31/353 , A61K31/357 , A61K31/405 , A61K31/41 , A61K31/4178 , A61K31/4184 , A61K31/44 , A61K31/453 , A61K31/454 , A61K31/535 , A61K31/536 , A61K38/00 , A61K38/12 , A61K45/00 , A61K47/30 , A61K47/32 , A61K47/34 , A61P3/10 , A61P9/00 , A61P27/02 , A61P31/10 , A61P43/00 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12
CPC分类号： A61K9/5138 , A61K9/0048 , A61K31/352 , A61K31/357 , A61K31/405 , A61K31/41 , A61K31/4184 , A61K31/44 , A61K31/536 , A61K38/12
摘要： Methods and compositions for prophylaxis and/or treatment of diseases of the eye of a patient resulting angiogenesis in the eye using antagonists of the integrin receptors alpha v beta 3 and /or alpha v beta 5. The compositions can be nanoparticles and are administered to the eye by injection into the sclera of the eye.
摘要翻译：使用整联蛋白受体αvβ3和/或αvβ5的拮抗剂预防和/或治疗患者眼睛疾病导致眼睛血管生成的方法和组合物。组合物可以是纳米颗粒，并且施用于眼睛注入眼睛的巩膜。

3. 发明申请

WO2005005389A3 MALONAMIDE DERIVATIVES 审中-公开
标题翻译：马来酰胺衍生物
公开(公告)号：WO2005005389A3
公开(公告)日：2005-03-24
申请号：PCT/EP2004006573
申请日：2004-06-18
申请人： MERCK PATENT GMBH , BRUGE DAVID , BUCHSTALLER HANS-PETER , WIESNER MATTHIAS , FINSINGER DIRK , BAUMGARTH MANFRED , SIRRENBERG CHRISTIAN , ZENKE FRANK , AMENDT CHRISTIANE , GRELL MATTHIAS
发明人： BRUGE DAVID , BUCHSTALLER HANS-PETER , WIESNER MATTHIAS , FINSINGER DIRK , BAUMGARTH MANFRED , SIRRENBERG CHRISTIAN , ZENKE FRANK , AMENDT CHRISTIANE , GRELL MATTHIAS
IPC分类号： A61P35/00 , C07C233/15 , C07D213/38 , C07D213/66 , C07D213/68 , C07D213/75 , C07D213/79 , C07D213/81 , C07D261/14 , C07D413/12 , A61K31/44
CPC分类号： C07D213/66 , C07C233/15 , C07D213/38 , C07D213/68 , C07D213/75 , C07D213/79 , C07D213/81 , C07D261/14 , C07D413/12
摘要： The present invention relates to malonamide derivatives of formula A-D-B-1, as inhibitors of raf-kinase and the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition.
摘要翻译：本发明涉及作为raf-激酶抑制剂的式A-D-B-1的丙二酰胺衍生物和式（I）化合物在制备药物组合物中的应用。

4. 发明申请

WO2004037789A8 METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS 审中-公开
标题翻译：甲基脲衍生物作为RAF-激酶抑制剂
公开(公告)号：WO2004037789A8
公开(公告)日：2004-12-16
申请号：PCT/EP0311134
申请日：2003-10-08
申请人： MERCK PATENT GMBH , BUCHSTALLER HANS-PETER , WIESNER MATTHIAS , SCHADT OLIVER , AMENDT CHRISTIANE , ZENKE FRANK , SIRRENBERG CHRISTIAN , GRELL MATTHIAS , FINSINGER DIRK
发明人： BUCHSTALLER HANS-PETER , WIESNER MATTHIAS , SCHADT OLIVER , AMENDT CHRISTIANE , ZENKE FRANK , SIRRENBERG CHRISTIAN , GRELL MATTHIAS , FINSINGER DIRK
IPC分类号： A61P29/00 , C07D213/68 , C07D213/79 , C07D213/81 , C07D401/12 , C07D409/12 , C07D417/12 , A61K31/44 , A61K31/4427 , C07D213/75 , C07D413/12
CPC分类号： C07D213/68 , A61K31/44 , A61K31/4439 , A61K45/00 , C07D213/75 , C07D213/79 , C07D213/81 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
摘要翻译：本发明涉及式（I）的亚甲基脲衍生物，式（I）化合物作为raf-激酶抑制剂的用途，式（I）化合物在制备药物组合物和治疗方法，包括将所述药物组合物施用于患者。

5. 发明申请

WO2004037789A3 METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS 审中-公开
标题翻译：甲基尿素衍生物作为RAF-激酶抑制剂
公开(公告)号：WO2004037789A3
公开(公告)日：2004-10-28
申请号：PCT/EP0311134
申请日：2003-10-08
申请人： MERCK PATENT GMBH , BUCHSTALLER HANS-PETER , WIESNER MATTHIAS , SCHADT OLIVER , AMENDT CHRISTIANE , ZENKE FRANK , SIRRENBERG CHRISTIAN , GRELL MATTHIAS , FINSINGER DIRK
发明人： BUCHSTALLER HANS-PETER , WIESNER MATTHIAS , SCHADT OLIVER , AMENDT CHRISTIANE , ZENKE FRANK , SIRRENBERG CHRISTIAN , GRELL MATTHIAS , FINSINGER DIRK
IPC分类号： A61P29/00 , C07D213/68 , C07D213/79 , C07D213/81 , C07D401/12 , C07D409/12 , C07D417/12 , A61K31/44 , A61K31/4427 , C07D213/75 , C07D413/12
CPC分类号： C07D213/68 , A61K31/44 , A61K31/4439 , A61K45/00 , C07D213/75 , C07D213/79 , C07D213/81 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
摘要翻译：本发明涉及式（I）的亚甲基脲衍生物，式（I）化合物作为raf-激酶抑制剂的用途，式（I）化合物在制备药物组合物和包括将所述药物组合物施用于患者。

6. 发明申请

WO0241910A8 METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE EYE 审中-公开
标题翻译：用于治疗眼睛疾病的方法和组合物
公开(公告)号：WO0241910A8
公开(公告)日：2004-02-26
申请号：PCT/EP0112526
申请日：2001-10-30
申请人： MERCK PATENT GMBH , BENDER HANS-MARKUS , HAUNSCHILD JUTTA , WIESNER MATTHIAS , LANG ULRICH , FRIEDLANDER MARTIN
发明人： BENDER HANS-MARKUS , HAUNSCHILD JUTTA , WIESNER MATTHIAS , LANG ULRICH , FRIEDLANDER MARTIN
IPC分类号： C07D311/22 , A61K9/00 , A61K9/10 , A61K9/51 , A61K31/352 , A61K31/353 , A61K31/357 , A61K31/405 , A61K31/41 , A61K31/4178 , A61K31/4184 , A61K31/44 , A61K31/453 , A61K31/454 , A61K31/535 , A61K31/536 , A61K38/00 , A61K38/12 , A61K45/00 , A61K47/30 , A61K47/32 , A61K47/34 , A61P3/10 , A61P9/00 , A61P27/02 , A61P31/10 , A61P43/00 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12
CPC分类号： A61K9/5138 , A61K9/0048 , A61K31/352 , A61K31/357 , A61K31/405 , A61K31/41 , A61K31/4184 , A61K31/44 , A61K31/536 , A61K38/12
摘要： Methods and compositions for prophylaxis and/or treatment of diseases of the eye of a patient resulting angiogenesis in the eye using antagonists of the integrin receptors alpha v beta 3 and /or alpha v beta 5. The compositions can be nanoparticles and are administered to the eye by injection into the sclera of the eye.
摘要翻译：使用整联蛋白受体αvβ3和/或αvβ5的拮抗剂预防和/或治疗患者眼睛疾病导致眼睛血管生成的方法和组合物。组合物可以是纳米颗粒，并且施用于眼睛注入眼睛的巩膜。

7. 发明申请

WO0158893A2 INDOL-3-YL DERIVATIVES 审中-公开
标题翻译：吲哚-3-基衍生物
公开(公告)号：WO0158893A2
公开(公告)日：2001-08-16
申请号：PCT/EP0100084
申请日：2001-01-05
申请人： MERCK PATENT GMBH , GOODMAN SIMON , GOTTSCHLICH RUDOLF , WIESNER MATTHIAS
发明人： GOODMAN SIMON , GOTTSCHLICH RUDOLF , WIESNER MATTHIAS
IPC分类号： C07D401/06 , A61K31/405 , A61K31/4178 , A61K31/4184 , A61K31/4439 , A61K31/506 , A61P7/02 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/00 , A61P35/00 , A61P43/00 , C07D209/18 , C07D209/20 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D409/06 , C07D417/06 , C07D417/14
CPC分类号： C07D401/12 , C07D209/18 , C07D403/12 , C07D417/14
摘要： Indol-3-yl derivatives of general formula (I), wherein A, B, X, R , R , R , R , R , n or m have the meanings given in Claim 1, and the physiologically unobjectionable salts or solvates thereof are integrin inhibitors and can be used for combating thrombosis, myocardial infarcts, coronary heart diseases, arteriosclerosis, inflammations, tumours, osteoporosis, rheumatic arthritis, macular degenerative diseases, diabetic retinopathy, infections and restenosis after angioplasty or in the event of pathological actions which are maintained or propagated by angiogenesis.
摘要翻译：通式（I）其中A，B，X，R <1>，R <2>，R <3>，R <4>，R <5>，N或者M的吲哚-3-基衍生物在根据权利要求1名的含义已经描述，以及它们的生理学可接受的盐或溶剂化物是整联蛋白抑制剂，并且可以用于防治血栓形成，心肌梗死，冠状动脉心脏疾病，动脉硬化，炎症，肿瘤，骨质疏松症，风湿性关节炎，黄斑变性疾病，糖尿病性视网膜病，感染和术后再狭窄用于血管成形术或在其通过血管发生维持或繁殖的病理过程。

8. 发明专利

ES2385329T3 Derivados de pirrol adecuados para el tratamiento de enfermedades proliferativas 未知
公开(公告)号：ES2385329T3
公开(公告)日：2012-07-23
申请号：ES04790859
申请日：2004-10-26
申请人： MERCK PATENT GMBH
发明人： FINSINGER DIRK , BUCHSTALLER HANS-PETER , BURGDORF LARS , WIESNER MATTHIAS , AMENDT CHRISTIANE , GRELL MATTHIAS , SIRRENBERG CHRISTIAN , ZENKE FRANK
IPC分类号： C07D401/12 , C07D207/32 , C07D207/337
摘要： Compuestos seleccionados del grupoN-Metilamida de ácido 4-{4-[5-(4-cloro-3-trifluormetil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(4-cloro-3-trifluormetil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{4-[5-(3-cloro-4-metil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{4-[5-(2-metoxi-5-trifluormetil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(3-cloro-4-metil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{4-[5-(3-cloro-6-metoxi-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(3-cloro-6-metoxi-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(2-metoxi-5-trifluormetil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(2,5-dimetoxi-4-cloro-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(4-brom-3-trifluormetil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(3-trifluormetil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(4-ter.-butil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(3,4-dicloro-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4- {3-[5-(4-cloro- 3- metil- 6- metoxi- fenilcarbamoil)- 1H- pirrol- 3- il]-fenoxi}-piridin- 2-carboxílico,N-Metilamida de ácido 4-{3-[5-(2,4-dimetoxi-5-trifluormetoxi-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(2-dimetilamino-5-trifluormetil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(2-(2-metilamino-etoxi)-5-metil-fenilcarbamoil)-1 H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(2-(2-dimetilamino-etoxi)-5-metil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,N-Metilamida de ácido 4-{3-[5-(2-[(2-dimetilamino-etil)-metil-amino]-5-metil-fenilcarbamoil)-1H-pirrol-3-il]-fenoxi}-piridin-2-carboxílico,así como sus solvatos, sales y estereoisómeros de utilidad farmacéutica, incluidas sus mezclas en todas lasproporciones.

9. 发明专利

ES2380201T3 Derivados de benzimidazol 未知
公开(公告)号：ES2380201T3
公开(公告)日：2012-05-09
申请号：ES04739891
申请日：2004-06-15
申请人： MERCK PATENT GMBH
发明人： BUCHSTALLER HANS-PETER , FINSINGER DIRK , WIESNER MATTHIAS , BURGDORF LARS , AMENDT CHRISTIANE , GRELL MATTHIAS , SIRRENBERG CHRISTIAN , ZENKE FRANK
IPC分类号： A61K31/4184 , A61K31/4439 , A61P35/00 , C07D401/12
摘要： Derivados de benzimidazol de fórmula I donde R6, R7 son independientemente entre sí H o A, A se selecciona independientemente entre el grupo compuesto por alquilo, alcoxi y alcoxialquilo, R8 se selecciona entre un grupo compuesto por H, A, cicloalquilo que comprende de 3 a 7 átomos de carbono, Hal, CH2Hal, CH (Hal) 2, C (Hal) 3, NO2 y (CH2) nCN, R9 y R10 se seleccionan independientemente entre un grupo compuesto por H, A, cicloalquilo que comprende de 3 a 7 átomos de carbono, Hal, CH2Hal, CH (Hal) 2, C (Hal) 3, NO2, (CH2) nCN, (CH2) nNR11R12, (CH2) nOR11, (CH2) nO (CH2) kNR11R12, (CH2) nCOOR12, (CH2) nCONR11R12, (CH2) nNR11COR13, (CH2) nNR11CONR11R12, (CH2) nNR11SO2A, (CH2) nSO2NR11R12, (CH2) nS (O) uR13, (CH2) nOC (O) R13, (CH2) nCOR13, (CH2) nSR11, CH=N-OA, CH2CH=N-OA, (CH2) nNHOA, (CH2) nCH=N-R11, (CH2) nOC (O) NR11R12, (CH2) nNR11COOR12, (CH2) nN (R11) CH2CH2OR13, (CH2) nN (R11) CH2CH2OCF3, (CH2) nN (R11) C (R13) HCOOR12, C (R13) HCOR12, (CH2) nN (R11) CH2CH2N (R12) CH2COOR12, (CH2) nN (R11) CH2CH2NR11R12, CH=CHCOOR11, CH=CHCH2NR11R12, CH=CHCH2NR11R12, CH=CHCH2OR13, (CH2) nN (COOR11) COOR12, (CH2) nN (CONH2) COOR11, (CH2) nN (CONH2) CONH2, (CH2) nN (CH2COOR11) COOR12, (CH2) nN (CH2CONH2) COOR11, (CH2) nN (CH2CONH2) CONH2, (CH2) nCHR13COR11, (CH2) nCHR13COOR11, (CH2) nCHR13CH2OR14, (CH2) nOCN y (CH2) nNCO, donde R11, R12 se seleccionan independientemente entre un grupo compuesto por H, A, (CH2) mAr3 y (CH2) mHet, o en NR11R12 R11 y R12 forman, junto con el átomo de N al que están unidos, un heterociclo de 5, 6 o 7 átomos que contiene opcionalmente 1 o 2 heteroátomos adicionales, seleccionados entre N, O y S, R13, R14 se seleccionan independientemente entre un grupo compuesto por H, Hal, A, (CH2) mAr4 y (CH2) mHet, Ar3, Ar4 son independientemente entre sí restos de hidrocarburos aromáticos que comprenden de 5 a 12 y, preferiblemente, de 5 a 10 átomos de carbono que opcionalmente están sustituidos con uno o más sustituyentes, seleccionados entre un grupo compuesto por A, Hal, NO2, CN, OR15, NR15R16, COOR15, CONR15R16, NR15COR16, NR15CONR15R16, NR16SO2A, COR15, SO2R15R16, S (O) uA y OOCR15, Het es un resto heterocíclico saturado, insaturado o aromático que está opcionalmente sustituido con uno o más sustituyentes seleccionados entre un grupo compuesto por A, Hal, NO2, CN, OR15, NR15R16, COOR15, CONR15R16, NR15COR16, NR15CONR15R16, NR16SO2A, COR15, SO2R15R16, S (O) uA y OOCR15, R15, R16 se seleccionan independientemente entre un grupo compuesto por H, A y (CH2) mAr6 donde Ar6 es un hidrocarburo aromático de 5 o 6 átomos que opcionalmente está sustituido con uno o más sustituyentes seleccionados entre un grupo compuesto por metilo, etilo, propilo, 2-propilo, terc-butilo, Hal, CN, OH, NH2 y CF3. 50 k, m y n son independientemente entre sí 0, 1, 2, 3, 4 o 5, R21 se selecciona independientemente entre las definiciones dadas para R13, R14 y p, r son independientemente entre sí 0, 1, 2, 3, 4 o 5, q es 0, 1, 2, 3 o 4, u es 0, 1, 2 o 3, y Hal se selecciona independientemente entre un grupo compuesto por F, Cl, Br y I; y las sales y solvatos fisiológicamente aceptables de los mismos.

10. 发明专利

CA2510167C DERIVATIVES OF ASIMADOLINE WITH COVALENTLY BONDED ACIDS 未知
公开(公告)号：CA2510167C
公开(公告)日：2011-05-24
申请号：CA2510167
申请日：2003-11-25
申请人： MERCK PATENT GMBH
发明人： WIESNER MATTHIAS , SEYFRIED CHRISTOPH
IPC分类号： C07D207/12 , A61K31/40
摘要： The invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidine-1-yl)-ethyl]-2,2-diphenyl acetamide comprising covalently bonded acids and to the salts, solvates and prodrugs of said derivatives. The invention also relates to the use of the derivatives as medicaments, to their use for producing a medicament and for producing a pharmaceutical composition, to a method for producing said pharmaceutical compositions, to pharmaceutical compositions obtained by said method and to a method for treating diseases, comprising the administration of the aforementioned pharmaceutical composition.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式